Ye Guangbin, Zhang Zhongwei, Li Yanli, Gao Li, Huang Wei, Ling Bo
School of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise 533000, China.
School of Pharmacy, Youjiang Medical University for Nationalities, Baise 533000, China.
Zhongguo Fei Ai Za Zhi. 2023 Jul 20;26(7):538-544. doi: 10.3779/j.issn.1009-3419.2023.102.25.
Myocyte enhancer factor 2D (MEF2D) can participate in the process of tumor lesions by regulating the transcription of oncogenes. In a previous study, MEF2D was demonstrated to enhance the proliferation and metastasis of lung adenocarcinoma cells A549 and H1299 by promoting the transcription of NUSAP1. The research aimed to explore the expression level and clinical significance of MEF2D in lung adenocarcinoma.
A total of 199 patients with lung adenocarcinoma were collected. Immunohistochemical staining was used to detect MEF2D expression levels in cancer and adjacent tissues. After the clinical and follow-up data were collated, the correlation between MEF2D expression level and clinical characteristics and prognosis of the patients was analyzed.
In the lung adenocarcinoma, the high expression rate of MEF2D in cancer tissues was significantly higher than that in adjacent tissues (P<0.05). According to immunohistochemical score, MEF2D expression level in lung adenocarcinoma tissues was correlated with tumor differentiation, N stage, M stage and intrapulmonary metastasis (P<0.05). Kaplan-Meier analysis showed that patients with low MEF2D expression had significantly better prognosis than patients with high MEF2D expression (P<0.05). Cox multivariate analysis showed that MEF2D expression level, M stage, N stage and bone metastasis of lung cancer were independent risk factors for prognosis of lung adenocarcinoma patients.
MEF2D expression level is closely related to the metastasis of lung adenocarcinoma and other clinical characteristics, and can be used as an independent risk factor for the prognosis of patients with lung adenocarcinoma, which has the potential to be developed as a clinical diagnosis and treatment target of lung adenocarcinoma.
肌细胞增强因子2D（MEF2D）可通过调控癌基因转录参与肿瘤病变过程。在前期研究中，已证实MEF2D通过促进NUSAP1转录增强肺腺癌细胞A549和H1299的增殖和转移。本研究旨在探讨MEF2D在肺腺癌中的表达水平及临床意义。
共收集199例肺腺癌患者。采用免疫组织化学染色检测癌组织及癌旁组织中MEF2D表达水平。整理临床及随访资料后，分析MEF2D表达水平与患者临床特征及预后的相关性。
在肺腺癌中，癌组织中MEF2D的高表达率显著高于癌旁组织（P<0.05）。根据免疫组织化学评分，肺腺癌组织中MEF2D表达水平与肿瘤分化、N分期、M分期及肺内转移相关（P<0.05）。Kaplan-Meier分析显示，MEF2D低表达患者的预后明显优于MEF2D高表达患者（P<0.05）。Cox多因素分析显示，MEF2D表达水平、肺癌M分期、N分期及骨转移是肺腺癌患者预后的独立危险因素。
MEF2D表达水平与肺腺癌转移及其他临床特征密切相关，可作为肺腺癌患者预后的独立危险因素，具有开发成为肺腺癌临床诊疗靶点的潜力。
